NeuroPace has beaten earnings in 3 of 4 quarters, grows revenue about 17% and burns little cash, with a 34.8% gap to the analyst target, but it depends on one product and single-source suppliers and is in a downtrend.
Thesis pillars
- Limited Cash Burn→Stable
- Earnings Beat Streak→Stable
- Revenue Growth Recovery→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 3, 2026
Neuropace, Inc. (NPCE) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $12.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend.
NeuroPace makes the RNS System, the only FDA-approved brain-responsive neuromodulation device for drug-resistant focal epilepsy, with more than 8,000 patients implanted as of December 31, 2025 targeting a U.S. population of about 575,000 eligible adults. The company generates... Read more
Sell if holding. Engine safety override at $12.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 57. Score 5.8/10, moderate confidence.
Passes 7/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 5d<=7d. Suitability: aggressive.
Recent developments
updated 2026-10-29Recent Developments — Neuropace, Inc.
Latest news
- NEWS This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday — benzinga Sep 18, 2026 positive
- NEWS Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18 — benzinga Sep 18, 2026 positive
- NEWS NeuroPace Raises FY2026 Sales Guidance from $99.000M-$101.000M to $99.500M-$101.500M vs $99.913M Est — benzinga Aug 11, 2026 positive
- NEWS NeuroPace Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $22.826M Beat $22.654M Estimate — benzinga Aug 11, 2026 positive
- NEWS 12 Health Care Stocks Moving In Wednesday's Pre-Market Session — benzinga Jul 29, 2026 neutral
Generated 2026-10-29T11:48:40Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductRNS System10-K Item 1A: 'We currently rely on our RNS System, which can only be marketed in the United States for use in adults with drug-resistant focal epilepsy, as our primary source of revenue.'
- HIGHSuppliersingle-source suppliers10-K Item 1A: 'We depend on a limited number of single-source suppliers and vendors in connection with the manufacture of our products, which makes us vulnerable to supply shortages and price fluctuations'
- MEDIUMCustomerDIXI Medical distribution agreement10-K Item 1A: 'With the expiration of our exclusive distribution agreement with DIXI Medical and loss of the associated revenue, our revenue growth, financial condition and results of operations may be'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -17.9%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $12.93: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 4.1:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 57. Prior stop was $12.02. Score 5.8/10, moderate confidence.
Analyst target: $17.40 (+34.6% upside). Prior stop was $12.02. Stop-loss: $12.02.
Concentration risk — Product: RNS System; Concentration risk — Supplier: single-source suppliers; Quality below floor (3.1 < 4.0).
Neuropace, Inc. trades at a P/E of N/A (forward -59.5). TrendMatrix value score: 8.4/10. Verdict: Sell.
16 analysts cover NPCE with a consensus score of 4.2/5. Average price target: $20.
What does Neuropace, Inc. do?NeuroPace makes the RNS System, the only FDA-approved brain-responsive neuromodulation device for drug-resistant focal...
NeuroPace makes the RNS System, the only FDA-approved brain-responsive neuromodulation device for drug-resistant focal epilepsy, with more than 8,000 patients implanted as of December 31, 2025 targeting a U.S. population of about 575,000 eligible adults. The company generates revenue from initial RNS System implants and recurring replacement-device sales as batteries reach end of service (average life of nearly 11 years), marketed through a direct U.S. sales force to roughly 200 Level 4 comprehensive epilepsy centers and an expanding base of community epileptologists and neurosurgeons.